Randomized multicentric italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia

Mario Renato Rossi, Giuseppe Masera, Maria Grazia Zurlo, Sergio Amadori Grazia Zurlo, Serenella Bagnulo, Modesto Carli, Luigi Zanesco, Giorgio Dini, Carlo Guazzelli, Alessandro Rosi, Enrico Madon, Luigi Nespoli, Guido Paolucci, Andreaa Pession, Paolo Tamaro

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

This paper reports the results of a multicentric randomized clinical trial on the treatment of first hematological relapse in childhood ALL. Induction treatment consisted of vincristine, adriamycin, L-asparaginase, and prednisone. Patients achieving complete remission were randomized to two maintenance regimens (A and B). Regimen A consisted of five different drug associations including VM26 and IDMTX in a sequential schedule; Regimen B was essentially classical Spiers schedule for the first year, followed by a milder treatment. Eighty-four of 102 evaluahle patients (82% achieved second complete remission. The two maintenance regimens were similar as regards duration of second complete remission (median duration A, 32 weeks; B, 37 weeks) and toxicity. Better results were obtained in patients relapsing after 12 months from suspension of treatment in first complete remission than in those relapsing within the first year off therapy (82.8% vs. 31.4% In group A fewer CNS relapses were reported. The two regimens produced results similar to those reported by other authors. The good prognosis in patients relapsing at least 1 year after treatment suspension in first complete remission must be emphasized.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalPediatric Hematology and Oncology
Volume3
Issue number1
DOIs
Publication statusPublished - 1986

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow
Recurrence
Toxicity
Suspensions
Appointments and Schedules
Therapeutics
Maintenance
Asparaginase
Vincristine
Prednisone
Doxorubicin
Relapse
Childhood
Randomized Controlled Trials
Pharmaceutical Preparations
Schedule

Keywords

  • Childhood ALL
  • Marrow relapse
  • Treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation

Cite this

Randomized multicentric italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia. / Rossi, Mario Renato; Masera, Giuseppe; Zurlo, Maria Grazia; Zurlo, Sergio Amadori Grazia; Bagnulo, Serenella; Carli, Modesto; Zanesco, Luigi; Dini, Giorgio; Guazzelli, Carlo; Rosi, Alessandro; Madon, Enrico; Nespoli, Luigi; Paolucci, Guido; Pession, Andreaa; Tamaro, Paolo.

In: Pediatric Hematology and Oncology, Vol. 3, No. 1, 1986, p. 1-9.

Research output: Contribution to journalArticle

Rossi, MR, Masera, G, Zurlo, MG, Zurlo, SAG, Bagnulo, S, Carli, M, Zanesco, L, Dini, G, Guazzelli, C, Rosi, A, Madon, E, Nespoli, L, Paolucci, G, Pession, A & Tamaro, P 1986, 'Randomized multicentric italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia', Pediatric Hematology and Oncology, vol. 3, no. 1, pp. 1-9. https://doi.org/10.3109/08880018609031195
Rossi, Mario Renato ; Masera, Giuseppe ; Zurlo, Maria Grazia ; Zurlo, Sergio Amadori Grazia ; Bagnulo, Serenella ; Carli, Modesto ; Zanesco, Luigi ; Dini, Giorgio ; Guazzelli, Carlo ; Rosi, Alessandro ; Madon, Enrico ; Nespoli, Luigi ; Paolucci, Guido ; Pession, Andreaa ; Tamaro, Paolo. / Randomized multicentric italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia. In: Pediatric Hematology and Oncology. 1986 ; Vol. 3, No. 1. pp. 1-9.
@article{d71c98db7f984149aabfae95408c3d1d,
title = "Randomized multicentric italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia",
abstract = "This paper reports the results of a multicentric randomized clinical trial on the treatment of first hematological relapse in childhood ALL. Induction treatment consisted of vincristine, adriamycin, L-asparaginase, and prednisone. Patients achieving complete remission were randomized to two maintenance regimens (A and B). Regimen A consisted of five different drug associations including VM26 and IDMTX in a sequential schedule; Regimen B was essentially classical Spiers schedule for the first year, followed by a milder treatment. Eighty-four of 102 evaluahle patients (82{\%} achieved second complete remission. The two maintenance regimens were similar as regards duration of second complete remission (median duration A, 32 weeks; B, 37 weeks) and toxicity. Better results were obtained in patients relapsing after 12 months from suspension of treatment in first complete remission than in those relapsing within the first year off therapy (82.8{\%} vs. 31.4{\%} In group A fewer CNS relapses were reported. The two regimens produced results similar to those reported by other authors. The good prognosis in patients relapsing at least 1 year after treatment suspension in first complete remission must be emphasized.",
keywords = "Childhood ALL, Marrow relapse, Treatment",
author = "Rossi, {Mario Renato} and Giuseppe Masera and Zurlo, {Maria Grazia} and Zurlo, {Sergio Amadori Grazia} and Serenella Bagnulo and Modesto Carli and Luigi Zanesco and Giorgio Dini and Carlo Guazzelli and Alessandro Rosi and Enrico Madon and Luigi Nespoli and Guido Paolucci and Andreaa Pession and Paolo Tamaro",
year = "1986",
doi = "10.3109/08880018609031195",
language = "English",
volume = "3",
pages = "1--9",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Randomized multicentric italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia

AU - Rossi, Mario Renato

AU - Masera, Giuseppe

AU - Zurlo, Maria Grazia

AU - Zurlo, Sergio Amadori Grazia

AU - Bagnulo, Serenella

AU - Carli, Modesto

AU - Zanesco, Luigi

AU - Dini, Giorgio

AU - Guazzelli, Carlo

AU - Rosi, Alessandro

AU - Madon, Enrico

AU - Nespoli, Luigi

AU - Paolucci, Guido

AU - Pession, Andreaa

AU - Tamaro, Paolo

PY - 1986

Y1 - 1986

N2 - This paper reports the results of a multicentric randomized clinical trial on the treatment of first hematological relapse in childhood ALL. Induction treatment consisted of vincristine, adriamycin, L-asparaginase, and prednisone. Patients achieving complete remission were randomized to two maintenance regimens (A and B). Regimen A consisted of five different drug associations including VM26 and IDMTX in a sequential schedule; Regimen B was essentially classical Spiers schedule for the first year, followed by a milder treatment. Eighty-four of 102 evaluahle patients (82% achieved second complete remission. The two maintenance regimens were similar as regards duration of second complete remission (median duration A, 32 weeks; B, 37 weeks) and toxicity. Better results were obtained in patients relapsing after 12 months from suspension of treatment in first complete remission than in those relapsing within the first year off therapy (82.8% vs. 31.4% In group A fewer CNS relapses were reported. The two regimens produced results similar to those reported by other authors. The good prognosis in patients relapsing at least 1 year after treatment suspension in first complete remission must be emphasized.

AB - This paper reports the results of a multicentric randomized clinical trial on the treatment of first hematological relapse in childhood ALL. Induction treatment consisted of vincristine, adriamycin, L-asparaginase, and prednisone. Patients achieving complete remission were randomized to two maintenance regimens (A and B). Regimen A consisted of five different drug associations including VM26 and IDMTX in a sequential schedule; Regimen B was essentially classical Spiers schedule for the first year, followed by a milder treatment. Eighty-four of 102 evaluahle patients (82% achieved second complete remission. The two maintenance regimens were similar as regards duration of second complete remission (median duration A, 32 weeks; B, 37 weeks) and toxicity. Better results were obtained in patients relapsing after 12 months from suspension of treatment in first complete remission than in those relapsing within the first year off therapy (82.8% vs. 31.4% In group A fewer CNS relapses were reported. The two regimens produced results similar to those reported by other authors. The good prognosis in patients relapsing at least 1 year after treatment suspension in first complete remission must be emphasized.

KW - Childhood ALL

KW - Marrow relapse

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0022885518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022885518&partnerID=8YFLogxK

U2 - 10.3109/08880018609031195

DO - 10.3109/08880018609031195

M3 - Article

VL - 3

SP - 1

EP - 9

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 1

ER -